Favre, Guillaume; Gerbier, Eva; Maisonneuve, Emeline; Pomar, Léo; Winterfeld, Ursula; Lepigeon, Karine; Bloemenkamp, Kitty W M; De Bruin, Odette; Eimir, Hurley; Nordeng, Hedvig; Siiskonen, Satu J; Sturkenboom, Miriam C J M; Baud, David; Panchaud, Alice (2023). COVID-19 related medicine utilization study in pregnancy - the COVI-PREG cohort. British journal of clinical pharmacology, 89(5), pp. 1560-1574. Wiley-Blackwell 10.1111/bcp.15611
|
Text
Brit_J_Clinical_Pharma_-_2022_-_Favre_-_COVID_19_related_medicine_utilization_study_in_pregnancy_the_COVI_PREG_cohort.pdf - Accepted Version Available under License Publisher holds Copyright. Download (1MB) | Preview |
|
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
Favre_BrJClinPharmacol_2023.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (480kB) | Request a copy |
OBJECTIVE
The aim was to describe the use of COVID-19 related medicines during pregnancy and their evolution between the early/late periods of the pandemic.
METHODS
Pregnant women tested positive for SARS-CoV-2 from March 2020, to July 2021, were included using the COVI-PREG registry. Exposure to the following COVID-19 related medicine were recorded: antibiotics, antivirals, hydroxychloroquine, corticosteroids, anti-interleukin-6 and immunoglobulins. We described the prevalence of medicines used, by trimester of pregnancy, maternal COVID-19 severity level and early/late period of the pandemic (before and after July 1 2020).
FINDINGS
We included 1,964 pregnant patients, tested positive for SARS-CoV-2. Overall, 10.4% (205/1964) received at least one COVID-19 related medicine including antibiotics (8.6%; 169/1694), corticosteroids (3.2%; 62/1964), antivirals (2.0%; 39/1964), hydroxychloroquine (1.4%; 27/1964), and anti-interleukin-6 (0.3%; 5/1964). The use of at least one COVID-19 related medicine was 3.1% (12/381) in asymptomatic, 4.2% (52/1233) in outpatients, 19.7% (46/233) in inpatients without oxygen, 72.1% (44/61) in requiring standard oxygen, 95.7% (22/23) in requiring high flow oxygen, 96.2% (25/26) in intubated and 57.1% (4/7) among patients who died. The proportion who received medicines to treat COVID-19 was higher before than after July 2020 (16.7% vs. 7.7%). Antibiotics, antivirals, and hydroxychloroquine had lower rates of use lately.
INTERPRETATION
Medicine use in pregnancy was increasing with disease severity. The trend toward increased corticosteroids use seems to be aligned with changing guidelines. Evidence is still needed regarding the effectiveness and safety of COVID-19 related medicines in pregnancy.
FUNDING
Research funded by the Swiss Federal Office of Public Health.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Medical Education > Institute of General Practice and Primary Care (BIHAM) |
UniBE Contributor: |
Gerbier, Eva Victoria, Maisonneuve, Emeline Louise Jacqueline, Panchaud Monnat, Alice Elke Martine |
Subjects: |
600 Technology > 610 Medicine & health 300 Social sciences, sociology & anthropology > 360 Social problems & social services |
ISSN: |
0306-5251 |
Publisher: |
Wiley-Blackwell |
Funders: |
[191] Swiss Federal Office of Public Health = Bundesamt für Gesundheit |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
24 Nov 2022 09:45 |
Last Modified: |
24 Nov 2023 00:25 |
Publisher DOI: |
10.1111/bcp.15611 |
PubMed ID: |
36417423 |
Uncontrolled Keywords: |
COVID-19 COVID-19 related medicine Drug use Medicine use Pharmaco-epidemiology Pregnancy Pregnant women SARS-CoV-2 |
BORIS DOI: |
10.48350/175108 |
URI: |
https://boris.unibe.ch/id/eprint/175108 |
Actions (login required)
 |
Edit item |